0RK9 Stock Chart & Stats
kr0.05
kr0.00(0.00%)
At close: 4:00 PM EDT
kr0.05
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr0.02 - kr0.90
Previous CloseN/A
Volume0.00
Average Volume (3M)160.27K
Market Cap
kr124.37M
Enterprise Valuekr122.60M
Total Cash (Recent Filing)kr16.61M
Total Debt (Recent Filing)kr29.93M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding6,909,175,300
10 Day Avg. Volume255,503
30 Day Avg. Volume160,273
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageThe sharp improvement in debt-to-equity reduces balance-sheet leverage relative to 2025 and may lower financial strain. This gives Alligator somewhat more flexibility to fund development, negotiate partnerships, or manage future financing needs despite its still-small equity base.
Narrower Net LossA smaller net loss year over year indicates some progress in controlling the earnings deficit, even though profitability remains deeply negative. If sustained, this direction could improve capital efficiency and extend the company’s ability to advance its pipeline between financings.
Improved Free Cash Flow TrendThe improvement in free cash flow compared with 2025 suggests cash usage has moved in a better direction. While this is not yet cash generation, continued progress could reduce the pace of financing needs and provide greater operational flexibility during clinical development.
Bears Say
Minimal And Declining RevenueMinimal, declining revenue shows that the company has not yet established meaningful commercial scale. That limits internally generated funding for research and clinical programs, leaving future progress dependent on partnerships, financing, or eventual successful product commercialization.
Deeply Negative ProfitabilityDeeply negative profitability indicates that current activities consume substantially more value than they generate. Persistent losses can constrain investment choices, weaken negotiating resilience in partnerships, and require continued access to external capital while the pipeline remains in development.
Persistent Cash BurnSubstantial and persistent operating cash burn means Alligator cannot currently sustain its operations from internally generated cash. Continued dependence on external funding increases financing pressure and could limit the pace or breadth of research and clinical development.
Alligator Bioscience AB News
0RK9 FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest share price was kr0.02 and its highest was kr0.90 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr124.37M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Oct 22, 2026 which is in 15 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Aug 26, 2026. The company reported -kr0.041 earnings per share for the quarter.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 6,909,175,300 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.041 in its last earnings report. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in GB:0RK9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―